269 related articles for article (PubMed ID: 25701312)
21. Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins.
Kato K; Mori H; Kito T; Yokochi M; Ito S; Inoue K; Yonezawa A; Katsura T; Kumagai Y; Yuasa H; Moriyama Y; Inui K; Kusuhara H; Sugiyama Y
Pharm Res; 2014 Jan; 31(1):136-47. PubMed ID: 23907530
[TBL] [Abstract][Full Text] [Related]
22. Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat.
Fan PW; Chen JZ; Allan Jaochico M; La H; Liu N; Mulder T; Cass RT; Durk M; Messick K; Valle N; Liu S; Lee W; Crawford JJ; Rudolf J; Murray LJ; Cyrus Khojasteh S; Wright M
Drug Metab Lett; 2016; 10(2):91-100. PubMed ID: 27063863
[TBL] [Abstract][Full Text] [Related]
23. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
24. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
25. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells.
Ingoglia F; Visigalli R; Rotoli BM; Barilli A; Riccardi B; Puccini P; Dall'Asta V
Biochim Biophys Acta; 2015 Jul; 1848(7):1563-72. PubMed ID: 25883089
[TBL] [Abstract][Full Text] [Related]
26. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity.
Nakamura T; Yonezawa A; Hashimoto S; Katsura T; Inui K
Biochem Pharmacol; 2010 Dec; 80(11):1762-7. PubMed ID: 20813096
[TBL] [Abstract][Full Text] [Related]
27. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.
More SS; Li S; Yee SW; Chen L; Xu Z; Jablons DM; Giacomini KM
Mol Cancer Ther; 2010 Apr; 9(4):1058-69. PubMed ID: 20371711
[TBL] [Abstract][Full Text] [Related]
28. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition.
Mikkaichi T; Yoshigae Y; Masumoto H; Imaoka T; Rozehnal V; Fischer T; Okudaira N; Izumi T
Drug Metab Dispos; 2014 Apr; 42(4):520-8. PubMed ID: 24459178
[TBL] [Abstract][Full Text] [Related]
29. Renal tubular secretion of varenicline by multidrug and toxin extrusion (MATE) transporters.
Kajiwara M; Masuda S; Watanabe S; Terada T; Katsura T; Inui K
Drug Metab Pharmacokinet; 2012; 27(6):563-9. PubMed ID: 22510868
[TBL] [Abstract][Full Text] [Related]
30. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
31. Differences in Metformin and Thiamine Uptake between Human and Mouse Organic Cation Transporter 1: Structural Determinants and Potential Consequences for Intrahepatic Concentrations.
Meyer MJ; Tuerkova A; Römer S; Wenzel C; Seitz T; Gaedcke J; Oswald S; Brockmöller J; Zdrazil B; Tzvetkov MV
Drug Metab Dispos; 2020 Dec; 48(12):1380-1392. PubMed ID: 33037045
[TBL] [Abstract][Full Text] [Related]
32. Influence of Cation Transporters (OCTs and MATEs) on the Renal and Hepatobiliary Disposition of [
Hernández-Lozano I; Mairinger S; Sauberer M; Stanek J; Filip T; Wanek T; Ciarimboli G; Tournier N; Langer O
Pharm Res; 2021 Jan; 38(1):127-140. PubMed ID: 33559045
[TBL] [Abstract][Full Text] [Related]
33. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
[TBL] [Abstract][Full Text] [Related]
34. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
[TBL] [Abstract][Full Text] [Related]
35. Impact of Experimental Conditions on the Evaluation of Interactions between Multidrug and Toxin Extrusion Proteins and Candidate Drugs.
Lechner C; Ishiguro N; Fukuhara A; Shimizu H; Ohtsu N; Takatani M; Nishiyama K; Washio I; Yamamura N; Kusuhara H
Drug Metab Dispos; 2016 Aug; 44(8):1381-9. PubMed ID: 27271370
[TBL] [Abstract][Full Text] [Related]
36. Stereoselective cell uptake of adrenergic agonists and antagonists by organic cation transporters.
Jensen O; Rafehi M; Tzvetkov MV; Brockmöller J
Biochem Pharmacol; 2020 Jan; 171():113731. PubMed ID: 31783011
[TBL] [Abstract][Full Text] [Related]
37. Trospium Chloride Transport by Mouse Drug Carriers of the Slc22 and Slc47 Families.
Gorecki M; Müller SF; Leidolf R; Geyer J
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375004
[TBL] [Abstract][Full Text] [Related]
38. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics.
Higgins JW; Bedwell DW; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2012 Jun; 40(6):1170-7. PubMed ID: 22407892
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes.
Song IS; Shin HJ; Shin JG
Xenobiotica; 2008 Sep; 38(9):1252-62. PubMed ID: 18728938
[TBL] [Abstract][Full Text] [Related]
40. Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis.
Jin HE; Hong SS; Choi MK; Maeng HJ; Kim DD; Chung SJ; Shim CK
Pharm Res; 2009 Mar; 26(3):549-59. PubMed ID: 19002567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
